AEON Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

FY2025Q2

FY2025Q3

-13.680

-86.95%

-0.350

-106.56%

-0.430

-96.27%

Estimates Revision

Stock Price

Go Up

+5.83%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Aeon Biopharma Inc (AEON.A) is 0.00, compared to its 5-year average forward P/E of -0.80. For a more detailed relative valuation and DCF analysis to assess Aeon Biopharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.80

Current PE

0.00

Overvalued PE

3.85

Undervalued PE

-5.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

AEON News & Events

Events Timeline

No data

News

5.0

2025-12-19Globenewswire

AEON Biopharma Grants 392,158 RSUs to New Employees

5.0

2025-12-19Newsfilter

AEON Biopharma Grants 392,158 Restricted Stock Units to New Employees

8.5

2025-12-15Globenewswire

AEON and Daewoong Pharmaceutical Finalize $15 Million Debt Exchange Agreement

People Also Watch

Frequently Asked Questions

What is Aeon Biopharma Inc (AEON) stock price today?

The current price of AEON is 1.09 USD — it has increased 0 % in the last trading day.

What is Aeon Biopharma Inc (AEON)'s business?

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine.

What is the price predicton of AEON Stock?

Wall Street analysts forecast AEON stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AEON is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Aeon Biopharma Inc (AEON)'s revenue for the last quarter?

Aeon Biopharma Inc revenue for the last quarter amounts to -2.53M USD, decreased -37.00 % YoY.

What is Aeon Biopharma Inc (AEON)'s earnings per share (EPS) for the last quarter?

Aeon Biopharma Inc. EPS for the last quarter amounts to -2596000.00 USD, decreased % YoY.

What changes have occurred in the market's expectations for Aeon Biopharma Inc (AEON)'s fundamentals?

The market is revising No Change the revenue expectations for AEON for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 5.83%.

How many employees does Aeon Biopharma Inc (AEON). have?

Aeon Biopharma Inc (AEON) has 5 emplpoyees as of January 09 2026.

What is Aeon Biopharma Inc (AEON) market cap?

Today AEON has the market capitalization of 13.20M USD.